在有蛋白酶抑制剂治疗史的患者中，HIV-1对成熟抑制剂PA-457的原发性基因型耐药性。
Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
作者信息
Malet Isabelle, Wirden Marc, Derache Anne, Simon Anne, Katlama Christine, Calvez Vincent, Marcelin Anne-Geneviève
机构信息
Laboratoire de Virologie, Université Pierre et Marie Curie (Paris 6), France.
出版信息
AIDS. 2007 Apr 23;21(7):871-3. doi: 10.1097/QAD.0b013e3280b079d9.
Sequences from 82 protease inhibitors (PI)-experienced patients were analysed for the presence of previously described in-vitro resistance mutations to PA-457 located in the C-terminal capside (H226Y, L231F, L231M) and in the N-terminal SP1 (A1V, A3T, A3V) within the CA-SP1 boundary domain. Overall, the CA-SP1 cleavage site was highly conserved in PI pre-treated patients and only one patient showed an L231M mutation. The impact of this mutation should be further addressed in vivo.
对82例曾使用蛋白酶抑制剂（PI）的患者的序列进行分析，以检测先前描述的位于C端衣壳（H226Y、L231F、L231M）和CA-SP1边界域内N端SP1（A1V、A3T、A3V）中对PA-457的体外耐药性突变。总体而言，CA-SP1切割位点在接受PI预处理的患者中高度保守，只有一名患者出现L231M突变。该突变的影响应在体内进一步研究。
Zotero 插件